ANZCTR search results

The GAP study is a research study which looks to compare a combination heart medicine called the "polypill" with existing treatments. The polypill has 4 different types of medicine in the one tablet. It contains aspirin, a cholesterol lowering medicine and two blood pressure lowering medicines. All four medicines have been available in Australia for a long time; the only difference is that they have been put into one tablet rather than four separate tablets. We think that this will make it easier for clients to take their medicine every day. We also think that by making these medicines easier to take it will be better at lowering blood pressure and cholesterol levels than taking many different tablets. This has not been proven and that is why we are conducting this important research to see if this is true. There is a merge of this trial with the Kanyini Polypill trial (of identical protocol and study design) into one trial to be renamed as 'Kanyini Guidelines Adherence with the Polypill (GAP)' trial under the ACTRN 12608000583347.

The Kanyini Guidelines Adherence with the Polypill study is a research study which looks to compare a combination heart medicine called the "polypill" with existing treatments. The polypill has 4 different types of medicine in the one tablet. It contains aspirin, a cholesterol lowering medicine and two blood pressure lowering medicines. All four medicines have been available in Australia for a long time and are known to be very safe; the only difference is that they have been put into one tablet rather than four separate tablets. We think that this will make it easier for clients to take their medicine every day. We also think that by making these medicines easier to take it will be better at lowering blood pressure and cholesterol levels than taking many different tablets. This has not been proven and that is why we are conducting this important research to see if this is true.

The PROMUS Element clinical trial – PLATINUM, is a prospective, multi-centre trial to evaluate the safety and effectiveness of the PROMUS Element Everolimus-Eluting Coronary Stent System compared with the PROMUS Everolimus-Eluting Coronary Stent System. Treatment will be in participants with up to 2 de novo (new or untreated) atherosclerotic coronary artery lesions. A separate coronary artery (de novo) narrowing is able to be treated with a commercial treatment (eg: stent such as PROMUS, balloon angioplasty, excluding brachytherapy) during the initial procedure. Up to 160 sites enrolling up to 1,532 patients. Follow up at hospital clinics 30 days, 6 and 12 months. Participants enrolled who did not receive the PROMUS Element or the PROMUS stent will complete follow up at this point. The Primary Endpoint is Target Lesion Failure at 12 months defined as ischaemia-driven Target Lesion Revascularisation (repeat treatment of narrowing), Myocardial Infarction (heart attack) related to the target vessel, or Cardiac Death (participant death) related to the target vessel.

PLATINUM QCA is a prospective, multicenter trial to assess PROMUS Element for the treatment of patients with a maximum of 1 de novo atherosclerotic coronary artery lesion of up to 34 mm in total length (by visual estimate) in native coronary arteries =2.25 mm to =4.25 mm in diameter (by visual estimate). Approximately 100 non-randomized patients at up to 20 sites are proposed to obtain clinical outcomes data for the PROMUS Element stent system. Follow up occurs at 30 days, 9 months and 12 months with both QCA and IVUS assessments at 9 months. The Primary Endpoint is Cardiac events at 30 days post-index procedure (Myocardial infarction (MI, Q-wave and non-Q wave) rate; Cardiac death rate; Target lesion failure (TLF) rate; Target lesion revascularization (TLR) rate; Stent thrombosis (ST) rate (definite or probable by Academic Research Consortium [ARC] definitions) with an efficacy endpoint of 9 month in-stent late loss and post-procedure incomplete apposition.

To determine the short term effects of a High Intensity Functional Exercise (HIFE) group program on clinical outcomes in older people in the sub-acute setting. Clinical outcomes include mobility, balance, length of stay and discharge destination.

Adequate nutrition is important to allow patients in the Intensive Care Unit the best chance of recovery from their illness. This is usually provided by feeding through a tube into the stomach. Unfortunately, many patients do not get enough nutrients from feeding into the gut, as the stomach and small intestine does not work normally. In these patients, symptoms such as diarrhoea and bloating are also common. We are doing research in this Intensive Care Unit to understand why the gut does not work normally in some patients and how this affects their absorption of nutrients. A greater understanding of how the gut functions during illness is important for treatment and to devise ways to improve the feeding of patients in Intensive Care.

The project will evaluate an injury assessment and treatment referral service for those injured in motor vehicle crashes in the ACT. This service will consist of a musculoskeletal specialist, supported by an education program. The primary research hypothesis for the program is that the provision of multidisciplinary musculoskeletal referral service will lead to improved health outcomes for injured people and reduce the duration of illness and associated costs. This will be established through a comparison with a control group of people injured before the service is established.

There is little evidence that indicates which anti-emetic (a drug to treat nausea and vomiting) is most effective in the Emergency and pre-hospital setting despite the widespread clinical use of the agents. The aim of this study is to undertake a randomised controlled trial in the pre-hospital setting to evaluate the efficacy of 3 commonly used anti-emetics.

The purpose of this study is to compare the penetration of Diclofenac with the penetration enhancer Tocopheryl Phosphate Mix (TPM) across intact skin against a currently marketed treatment Voltaren Gel. For the first visit you will be randomly allocated to receive a topical application of one of TPM/Diclofenac HS, TPM/Diclofenac LS or Voltaren Gel applied to your back. At the second visit you will receive a topical application of another one of TPM/Diclofenac HS, TPM/Diclofenac LS or Voltaren Gel, different to the treatment you received at the first visit. At the third visit you will receive a topical application of the other one of TPM/Diclofenac HS, TPM/Diclofenac LS or Voltaren Gel, different to the treatments you received at the first and second visits. At the fourth visit, you will receive all three treatments and undergo a procedure called skin stripping to evaluate how well Diclofenac penetrates the skin. For each of the visits you will stay at the study centre for approximately 6 hours after the gel has been applied. You will then be required to return to the study centre for approximately 1 hour for a follow up visit. Blood samples will be collected in visits 1, 2 and 3 (8 samples per visit) by either cannula or venipuncture. A total of 192 mL of blood will be collected during the study, which includes the amount required for the clinical laboratory tests and for the measurement of Diclofenac in your blood.

The study will explore the use of health professional facilitated sessions aiming to challenge perceived barriers to participating in physical activity amongst Macedonian and Polish older people (55+) in the Western Metropolitan Region (WMR) of Melbourne. The study has the following aims: · to determine whether a health professional facilitated education intervention increases physical activity and fitness amongst the target population; · to determine whether a health professional facilitated education intervention assists the target population to progress in their readiness to undertake physical activity; and The primary study hypothesis for the project is: · that a health professional facilitated education session program targeting identified barriers to physical activity for two CALD groups (Polish and Macedonian) will result in improved readiness to undertake physical activity and improved participation in physical activity.